Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:18 PM
Ignite Modification Date:
2025-12-24 @ 5:18 PM
NCT ID:
NCT02097550
Eligibility Criteria:
Inclusion Criteria:
* Stage 3a (eGFR 45-59) plus poorly controlled risk factors for CKD progression and/or cardiovascular disease morbidity/mortality). Our intervention is appropriate for patients with stage 3a CKD who are not yet optimized for kidney protection (in the setting of proteinuria) with ACE-inhibitors/ARBS, hypertension, diabetes and cardiovascular disease treatment. Our intervention messages promote medication classes for the optimization of these conditions and thus are appropriate for patients with stage 3a CKD who are not yet controlled for these conditions
* Stage 3b chronic kidney disease (defined as eGFR 30-44): The rationale for including patients with stage 3b CKD (defined by eGFR 30-44) but not stage 3a (eGFR 45-59) is to reduce the possibility of misclassification of those with higher eGFRs (who have little or no underlying kidney dysfunction) and to respond to evidence that patients with stage 3b CKD have much higher rates of progression to kidney failure than those with stage 3a. We chose the following inclusion criteria to optimize the balance between generalizability, participant safety, treatment adherence, and retention.
* Having a primary care provider (PCP) at UCSF, defined as an identified individual provider or provider group from whom the participant receives ongoing medical care, if needed;
* Not pregnant at study assessment.
* The ability to use a computer or smartphone
* The ability to understand English
Exclusion Criteria:
* Severe hypertriglyceridemia (TG\>500 mg/dL)
* Hyperkalemia (K\>5.0 mEq/L)
* Serious illness likely to preclude study completion
* Pregnancy
* Intolerance/allergy to all indicated CKD medications
* Medication management for CKD (i.e., with all of the medications/medication classes targeted for promotion by the eHealth intervention) has already been optimized
* Has never used MyChart: because MyChart use indicates a minimum level of existing familiarity with and use of eHealth materials
* Having no access to a computer or smartphone
* Plans to change primary care site.
* Family/household member of another study participant or of a study staff member;
* Already enrolled or planning to enroll in a research study that would limit full participation in this trial or confound interpretation of its results;
* Investigator discretion for clinical safety or protocol adherence reasons.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02097550
Study Brief:
Protocol Section:
NCT02097550